BRIDGEWATER, N.J., Sept. 29, 2017 /PRNewswire/ -- Nevakar LLC, a privately-held specialty pharmaceutical company developing innovative therapies within the injectable and ophthalmic space, today announced a collaborative research agreement with Princeton University, using Princeton's proprietary nanoparticle platform to develop unique formulations of oncology and anti-infective drug molecules.
"This research agreement with Princeton University furthers our efforts to develop enhanced and innovative products that leverage novel scientific and technology platforms," said Navneet Puri, Ph.D., founder and chief executive officer of Nevakar.
About Princeton University
Princeton is a not-for-profit institution of higher education dedicated to advancing learning through scholarship, research, and teaching of unsurpassed quality, with an emphasis on undergraduate, and doctoral education that is distinctive among the world's great universities, and with a persuasive commitment to serve the nation and the world.
Nevakar is a specialty pharmaceutical company focused on therapies within the injectable and ophthalmic space. Our goal is to develop enhanced products that address unmet clinical and/or commercial needs of currently FDA-approved molecules, through intensive R&D and clinical efforts. Nevakar has a comprehensive infrastructure for product development at its New Jersey facilities. More information about Nevakar can be found at www.nevakar.com.
Chief Financial Officer
At Rx Communications Group:
SOURCE Nevakar LLC